A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
(201)-510-0950